Postoperative Intensity-Modulated Radiotherapy in Low-Risk Endometrial Cancers: Final Results of a Phase I Study

Macchia, G.; Cilla, Savino; Ferrandina, Gabriella; Padula, Gilbert D. A.; Deodato, Francesco; Digesù, Cinzia; Caravatta, L.; Picardi, V.; Corrado, Giacomo; Piermattei, Angelo; Valentini, Vincenzo; Cellini, Numa; Scambia, Giovanni; Morganti, Alessio Giuseppe

doi:10.1016/j.ijrobp.2009.04.091

Cited by 9 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surrounding critical structures including the bladder, rectum, small bowel and femoral heads were contoured as OARs in planning CT images according to ICRU 38 recommendations [5]. 3D expansion of the CTV2 by 5 mm isotropically generated the PTV, which is consistent with the literature [6,7].…”

Section: Methodsmentioning

confidence: 66%

See 1 more Smart Citation

Evaluation of stereotactic body radiotherapy (sbrt) boost in the management of endometrial cancer

Demiral

Beyzadeoğlu²,

Uysal³

et al. 2013

neo

View full text Add to dashboard Cite

The purpose of this study is to evaluate the use of linear accelerator (LINAC)-based stereotactic body radiotherapy (SBRT) boost with multileaf collimator technique after pelvic radiotherapy (RT) in patients with endometrial cancer. Consecutive patients with endometrial cancer treated using LINAC-based SBRT boost after pelvic RT were enrolled in the study. All patients had undergone surgery including total abdominal hysterectomy and bilateral salpingo-oophorectomy ± pelvic/paraortic lymphadenectomy before RT. Prescribed external pelvic RT dose was 45 Gray (Gy) in 1.8 Gy daily fractions. All patients were treated with SBRT boost after pelvic RT. The prescribed SBRT boost dose to the upper two thirds of the vagina including the vaginal vault was 18 Gy delivered in 3 fractions with 1-week intervals. Gastrointestinal and genitourinary toxicity was assessed using the Common Terminology Criteria for Adverse Events version 3 (CTCAE v3).Between April 2010 and May 2011, 18 patients with stage I-III endometrial cancer were treated with LINAC-based SBRT boost after pelvic RT. At a median follow-up of 24 (8-26) months with magnetic resonance imaging (MRI) and gynecological examination, local control rate of the study group was 100 % with negligible acute and late toxicity.LINAC-based SBRT boost to the vaginal cuff is a feasible gynecological cancer treatment modality with excellent local control and minimal toxicity that may replace traditional brachytherapy boost in the management of endometrial cancer.

show abstract

Section: Methodsmentioning

confidence: 66%

“…Macchia et al [6] used vaginal cylinder as SBRT reference for patients in the postoperative setting of endometrial cancer. Doses of 25 Gy and 30 Gy were delivered within 5 consecutive daily fractions to the upper two thirds of vagina.…”

Section: Discussionmentioning

confidence: 99%